SMMTSummit TherapeuticsNot started yet
A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer
Renal Cell Carcinoma, Clear Cell
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 100 (planned)
- Started
- Oct 19, 2026
- Main results expected
- Apr 12, 2029
- Fully finished
- Dec 12, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR)
Measured over: From randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.
Adverse Events (AEs)
Measured over: At the time of initiation of the first dose through 90 days after the last dose of study treatment.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07877194 · record last updated 2026-10-16 · checked 2026-11-09 15:47 UTC